Clinical trials
Phase 2 Lower Urinary Tract Symptoms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Terminated | 5 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Inc | 3 |
| Taiho Pharmaceutical Co., Ltd. | 3 |
| Boehringer Ingelheim | 2 |
| Medstar Health Research Institute | 2 |
| Aga Khan University | 1 |
| Beni-Suef University | 1 |
| Buddhist Tzu Chi General Hospital | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Changhai Hospital | 1 |
| Clinical Academic Center (2CA-Braga) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lower Urinary Tract Symptoms | 29 |
| Prostatic Hyperplasia | 7 |
| Hematuria | 2 |
| Pain | 2 |
| Prostatic Neoplasms | 2 |
| Spinal Cord Injuries | 2 |
| Spinal Dysraphism | 2 |
| Urinary Bladder Neck Obstruction | 2 |
| Urinary Bladder, Overactive | 2 |
| Urinary Incontinence | 2 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.